LENVAKAST-4 Capsules LENVAKAST-4 contains Lenvatinib, an oral multi-kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1, FGFR2, FGFR3, FGFR4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET proto-oncogenes. By blocking these receptor tyrosine kinases, lenvatinib inhibits pathogenic angiogenesis, tumor cell growth, and disease progression. It is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), and in combination with pembrolizumab or everolimus for advanced renal cell carcinoma (RCC).